Extract to table
Pull the structured facts out of a document: parties, dates, amounts, obligations.
Extract to table / termination-strategy-litigation-risk-memo.docx
termination-strategy-litigation-risk-memo.docx
Parties
Secretary Penterra Pharmaceuticals Corp
Harkness LLP
Penterra Pharmaceuticals Corp
Cole LLP
Fidelis National Escrow Corp
Broadleaf Scientific Consulting LLC
Dates
September 15, 2024
August 14, 2024
August 22, 2024
June 10, 2024
August 25, 2024
August 27, 2024
August 28, 2024
September 2, 2024
September 3, 2024
June 30, 2024
Amounts
$900,000,000
$14.2
$4.87
$2.1
$87.3
$420
$900
$180,000,000
$2,500,000
$717,500,000
Obligations
A buyer claiming MAE must demonstrate an effect that is "material when viewed from the long-term perspective of a reasonable acquiror
The disproportionate impact exception provides that any excluded event, change, or development that has a materially disproportionate impact on the Company relative to other companies operating in the biotechnology or pharmaceutical industries shall not be excluded from the definition of Material Adverse Effect
12 is that all closing conditions must be satisfied